ArticleBMC urology2025
Proteinuria reduction by and safety of finerenone in Chinese patients with CKD without diabetes: a real-world retrospective study.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThis retrospective study aimed to assess the effectiveness and safety of finerenone in patients with chronic kidney disease (CKD) without diabetes mellitus (DM), as evidence from both clinical trials and real-world data remains limited.
methodsPatients with CKD and without DM were enrolled in this study from December 2022 to August 2023. In addition to standard CKD treatment, patients received finerenone. Twenty-four-hour urinary protein (UTP) levels, estimated glomerular filtration rate (eGFR), and serum potassium (sK⁺) levels were measured on a monthly basis for 5 months from the time of enrolment.
resultsA total of 43 patients were enrolled, with a baseline 24-h UTP of 5.58 ± 7.67 g. The mean age of the patients was 50.98 ± 13.00 years, and 30 individuals (69.8%) were male. Membranous nephropathy was diagnosed in 20 patients (46.5%). During follow-up, the 24-h UTP levels significantly decreased, with a median reduction of 2.46 g (IQR: 0.2015-2.609; P < 0.01) and a percentage change of 60.86% (IQR: 35.625-87.062%) being observed. No significant changes were observed in the eGFR (P = 0.713) or sK⁺ levels (P = 0.400), which remained within a range of 3.5-5.5 mmol/L. No rehospitalizations due to hyperkalaemia occurred.
conclusionFinerenone treatment significantly reduced proteinuria over the follow-up period, with minimal effects on potassium and the eGFR being observed, thereby supporting its safety and efficacy in the treatment of CKD patients without DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.